BIRMINGHAM, Ala.--(BUSINESS WIRE)--TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development ...

primarily by inhibiting the activation of the ROS-TXNIP-NLRP3 pathway (Wang et al., 2020). Regarding cardiac fibrosis, FMN improved mitochondrial function by downregulating MOAB mRNA expression and ...

Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, P. R. China Key Laboratory of Advanced Technologies of Materials Ministry of Education, School ...

There is solid evidence for the cleavage of VgrG2B by Caspase 11 and the generation of fragments that inhibit activity of the NLRP3 inflammasome. This work should be of interest to immunologists and ...

Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge’s platform, ...

These results indicate that TRIM30 is a negative regulator of NLRP3 mediated inflammatory responses. Potential role of micro RNAs in mediating ROS-induced inflammasome activation Figure 2. Role played ...